Josip Katić1, Ante Anić2, Toni Brešković2, Zrinka Jurišić2. 1. Clinic for Heart and Cardiovascular Diseases, University Hospital Split, Spinčićeva 1, 21000, Split, Croatia. josipkati@gmail.com. 2. Clinic for Heart and Cardiovascular Diseases, University Hospital Split, Spinčićeva 1, 21000, Split, Croatia.
Abstract
PURPOSE: Catheter ablation is a cornerstone of the therapy for paroxysmal atrial fibrillation. The importance of effective lesion size formation during pulmonary vein isolation is gauged through conduction recovery and recurrence of arrhythmia. Therefore, the lesion size index (LSI) is designed to utilize traditional intraprocedural parameters and predict procedural success. The impact of the optimal LSI index and the respective segments of the pulmonary veins has not been commonly evaluated. We aimed to assess whether higher and targeted LSI on the different segments of pulmonary veins could actually lead to better clinical outcomes of paroxysmal atrial fibrillation ablation. METHODS: Retrospective analyses of drug-refractory paroxysmal atrial fibrillation patients who underwent first catheter ablation were conducted. Targeted LSI of 6.5 at the anterior wall and 5.2 at the posterior wall, roof, and floor of the pulmonary vein was applied. The primary endpoint was defined as arrhythmias recurrence assessed by routine electrocardiograms and 24-h ambulatory electrocardiographic monitoring at 3, 6, and 12 months post-ablation. RESULTS: Among the included 39 patients, the single-procedure 12-month freedom from arrhythmias was reached in 92.3% of patients. Interestingly, there was no tendency towards an increased number of adverse effects using a higher LSI index. CONCLUSIONS: Atrial fibrillation ablation guided by targeted LSI value showed efficiency on the freedom from arrhythmias during 1-year follow-up period without harmful effects.
PURPOSE: Catheter ablation is a cornerstone of the therapy for paroxysmal atrial fibrillation. The importance of effective lesion size formation during pulmonary vein isolation is gauged through conduction recovery and recurrence of arrhythmia. Therefore, the lesion size index (LSI) is designed to utilize traditional intraprocedural parameters and predict procedural success. The impact of the optimal LSI index and the respective segments of the pulmonary veins has not been commonly evaluated. We aimed to assess whether higher and targeted LSI on the different segments of pulmonary veins could actually lead to better clinical outcomes of paroxysmal atrial fibrillation ablation. METHODS: Retrospective analyses of drug-refractory paroxysmal atrial fibrillation patients who underwent first catheter ablation were conducted. Targeted LSI of 6.5 at the anterior wall and 5.2 at the posterior wall, roof, and floor of the pulmonary vein was applied. The primary endpoint was defined as arrhythmias recurrence assessed by routine electrocardiograms and 24-h ambulatory electrocardiographic monitoring at 3, 6, and 12 months post-ablation. RESULTS: Among the included 39 patients, the single-procedure 12-month freedom from arrhythmias was reached in 92.3% of patients. Interestingly, there was no tendency towards an increased number of adverse effects using a higher LSI index. CONCLUSIONS: Atrial fibrillation ablation guided by targeted LSI value showed efficiency on the freedom from arrhythmias during 1-year follow-up period without harmful effects.
Authors: Karl-Heinz Kuck; Vivek Y Reddy; Boris Schmidt; Andrea Natale; Petr Neuzil; Nadir Saoudi; Josef Kautzner; Claudia Herrera; Gerhard Hindricks; Pierre Jaïs; Hiroshi Nakagawa; Hendrik Lambert; Dipen C Shah Journal: Heart Rhythm Date: 2011-08-26 Impact factor: 6.343
Authors: Jose Osorio; Tina D Hunter; Anil Rajendra; Paul Zei; Joshua Silverstein; Gustavo Morales Journal: J Cardiovasc Electrophysiol Date: 2021-04-06
Authors: Jason G Andrade; George A Wells; Marc W Deyell; Matthew Bennett; Vidal Essebag; Jean Champagne; Jean-Francois Roux; Derek Yung; Allan Skanes; Yaariv Khaykin; Carlos Morillo; Umjeet Jolly; Paul Novak; Evan Lockwood; Guy Amit; Paul Angaran; John Sapp; Stephan Wardell; Sandra Lauck; Laurent Macle; Atul Verma Journal: N Engl J Med Date: 2020-11-16 Impact factor: 91.245
Authors: Douglas L Packer; Daniel B Mark; Richard A Robb; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Peter A Noseworthy; Yves D Rosenberg; Neal Jeffries; L Brent Mitchell; Greg C Flaker; Evgeny Pokushalov; Alexander Romanov; T Jared Bunch; Georg Noelker; Andrey Ardashev; Amiran Revishvili; David J Wilber; Riccardo Cappato; Karl-Heinz Kuck; Gerhard Hindricks; D Wyn Davies; Peter R Kowey; Gerald V Naccarelli; James A Reiffel; Jonathan P Piccini; Adam P Silverstein; Hussein R Al-Khalidi; Kerry L Lee Journal: JAMA Date: 2019-04-02 Impact factor: 56.272
Authors: Luca De Mattia; Martino Crosato; Stefano Indiani; Elena Causin; Claudia Licciardello; Paolo Antonio Maria Squasi; Alessandro De Leo; Vittorio Calzolari Journal: J Atr Fibrillation Date: 2018-04-30
Authors: Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins Journal: Eur Heart J Date: 2021-02-01 Impact factor: 29.983
Authors: Mark J Mulder; Michiel J B Kemme; Amaya M D Hagen; Luuk H G A Hopman; Peter M van de Ven; Herbert A Hauer; Giovanni J M Tahapary; Marco J W Götte; Albert C van Rossum; Cornelis P Allaart Journal: Int J Cardiol Heart Vasc Date: 2020-07-03